Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Halozyme Therapeutics

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

- PMLiVE

FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

- PMLiVE

Candel announces promising results for immunotherapy candidate in pancreatic cancer

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

- PMLiVE

Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

More than 90% of patients with locally advanced disease are not eligible for surgery

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

- PMLiVE

Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

- PMLiVE

Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

- PMLiVE

BMS’ Opdivo combo misses the mark in pancreatic cancer

Failed to reach primary endpoint of progression-free survial

- PMLiVE

NantKwest rockets on promising pancreatic cancer data

One patient demonstrated a complete response following treatment

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

- PMLiVE

AZ, Merck’s Lynparza narrowly scores FDA approval for pancreatic cancer

Committee voted seven to five in favour of PARP inhibitor

- PMLiVE

Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

Will now focus on its novel drug delivery platform to drive business growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links